Elucidating Acquired PARP Inhibitor Resistance in Advanced Prostate Cancer

Evaluating samples from patients with metastatic CRPC treated in the TOPARP-B trial, the authors identifed reversion mutations in most BRCA2/PALB2-mutated tumors by end of treatment.